SARS-COV-2 rbd nanoparticle

SARS-COV-2 rbd nanoparticle has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Sep 9, 2021: “An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice”.

Intervention

1 paper studies it2 findingsUpdated

See all 1 papers on SARS-COV-2 rbd nanoparticle

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: Daiichi Sankyo Europe and 8 more
  • 2 of 2 findings with company ties
  • Animals1

What did studies of SARS-COV-2 rbd nanoparticle find?

2

Studies of SARS-COV-2 rbd nanoparticle measured 2 outcomes: cross-neutralizing antibodies and immune response.

Cross-neutralizing antibodies

upin mice1

1 study
  1. SARS-COV-2 rbd nanoparticle increases cross-neutralizing antibodies in mice (compared to other oil-in-water emulsions or AS01B).

    “induced the highest levels of cross-neutralizing antibodies compared to other oil-in-water emulsions or AS01B”

    Animalscompared to other oil-in-water emulsions or AS01B

    An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

More on Cross-neutralizing antibodies

Immune response

upin mice1

1 study
  1. SARS-COV-2 rbd nanoparticle induces immune response in mice.

    “SARS-CoV-2 receptorbinding domain (RBD) displayed as a protein nanoparticle (RBD-NP) was a highly effective antigen”

    Animals

    An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

More on Immune response

Latest